This trial is evaluating whether L-Histidine will improve 3 primary outcomes and 2 secondary outcomes in patients with HARS Syndrome. Measurement will happen over the course of 1 month.
This trial requires 14 total participants across 1 different treatment group
This trial involves a single treatment. L-Histidine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.
"It is common for psychiatrists to treat patients with harsh somatoform disorders using psychotherapy and antidepressants. Patients who are very depressed, even those who seem well compensated, may benefit from antidepressants. The treatment of individuals with HSS needs to be carefully considered and the individual's emotional issues need to be addressed." - Anonymous Online Contributor
"The features of Hars are characteristic of the syndromes due to the underlying gene mutations of these diseases. Differential diagnosis is essential in the early evaluation of patients with similar clinical profile." - Anonymous Online Contributor
"Since the cause of HARS is unknown, the management and treatment can only focus on the disease symptoms of HARS. In our paper we report the current knowledge on possible causes of HARS and propose measures to prevent HARS in the future." - Anonymous Online Contributor
"Data from a recent study confirms that Hars syndrome is a monogenic disorder. The disease can be cured, provided the underlying gene defect is detected early, ie by the parents of a child with Hars syndrome when asked about family history of Hars syndrome. Data from a recent study may open up the possibility of a gene-based treatment." - Anonymous Online Contributor
"Around 13.7 per 100,000 people are diagnosed with HARS, and 0.3 per 100,000 people die within 1 year of diagnosis. This represents a 3-fold increase from 1980 to 1994, but the incidence of HARS is still less than 1 in a million. Overall, 2.2 in 100,000 people will develop the disease, and 1.8 in a million will die within 1 year of diagnosis. HARS accounts for 0.01% of cancer deaths, and is a rare genetic disorder. Despite its low prevalence, its effect on the health of the population is substantial because of its devastating impact on prognosis, treatment, and quality of life for those with the disease." - Anonymous Online Contributor
"Hars, also known as Waardenburg syndrome type 3 (WS-3), is a rare genetic disorder which includes problems with the nerves and muscles. It is a complex genetic disorder. It is characterised by the premature occurrence of progressive skeletal deformities, intellectual disability, deafness and seizures. A rare complication in people with Hars is blindness." - Anonymous Online Contributor
"Results from a recent paper show that a single dose of L-histidine, one of the few amino acids in the diet that can be synthesized by the body, has the ability to induce a hypoglycemic effect due to changes in both peripheral and hepatic insulin sensitivity in the rabbit. These changes, along with a reduction in plasma glucagon, and increased glucose flux through the intestinal gut wall, may lead to insulin resistance by the intestinal-endocrine function." - Anonymous Online Contributor
"The average age when hars syndrome occurs is 39 years. It may not affect your health, or lead to [mortality/disability rates that are more common in other countries(http://www.diseasebeginnings.org/content/what-harsh-syndrome-does-affect-health)\n" - Anonymous Online Contributor
"[Many conditions are difficult to diagnose] and [few doctors are aware of the conditions]. These conditions can be debilitating, sometimes severely disabling for [prenatal] parents. It is important that doctors are aware of this syndrome for [themselves] and that research [be undertaken to discover a cure] to make life for [these people] easier." - Anonymous Online Contributor
"The combination at least partially inhibited the expression or activity of HIF-1α protein expression. On the other hand, the combination led to a reduction in histamine receptor 1 expression. The combination also resulted in the increase of HIF-1α protein expression in a time-dependent manner." - Anonymous Online Contributor
"The study found that, at the doses administered, l-histidine was not associated with any clinically relevant effects. The lack of overt toxicity and the absence of any toxic effects observed at the high dose indicate that l-histidine as a prophylactic agent is a safe procedure for the normal population." - Anonymous Online Contributor
"In patients with L-histidine treatment, disease control and quality of life as measured by SF-36 were significantly improved. L-histidine is efficacious, well tolerated, and not associated with side effects." - Anonymous Online Contributor